We treated isogenic HAP1-KO MBD4 and HAP1-WT cell lines with camptothecin, doxorubicin, gemcitabine, cytarabine, paclitaxel, and dacarbazine, an alkylating agent commonly used to treat uveal melanoma patients (together with its active form, MTIC). This evidence concerns the gene MBD4 and uveal melanoma.